CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
CRSPCRISPR Therapeutics(CRSP) ZACKS·2024-08-06 23:41

CRISPR Therapeutics (CRSP) incurred a loss of 1.49pershareinthesecondquarterof2024,whichwaswiderthantheZacksConsensusEstimateofalossof1.49 per share in the second quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 1.37. In the year-ago period, the company had incurred a loss of 98 cents per share.The company’s total revenues, though negligible, were entirely from grant revenues, which were 0.5millioninthesecondquarter.ThereportedfiguresignificantlymissedtheZacksConsensusEstimateof0.5 million in the second quarter. The reported figure significantly missed the Zacks Consensus Estimate of 8 million.In the year-ago quarter, the company generated collabora ...